
Opinion|Videos|February 5, 2025
Recent FDA Approvals in NMIBC
Author(s)Mark D. Tyson, MD, MPH, Gary D. Steinberg, MD
Panelists discuss how FDA approvals have expanded options for BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), with pembrolizumab, nogapendekin alfa inbakicept-pmln, and nadofaragene firadenovec-vncg offering new immunotherapy and gene therapy approaches.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How has the treatment landscape of NMIBC changed in recent years to provide better options for patients?
- Provide an overview of recent FDA approvals, including for the treatment of high-risk, BCG-unresponsive NMIBC (pembrolizumab [PD-1 inhibitor], nogapendekin alfa inbakicept-pmln [immunotherapy], and nadofaragene firadenovec-vncg [gene therapy]).
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The ArteraAI Prostate Test: What It Is and How It Works
2
HHS requests testosterone therapy label updates, citing new safety data
3
Retrospective study suggests differences in OAB therapy persistence among older adults
4
FDA gives nod to feasibility study of NanoKnife IRE for benign prostatic hyperplasia
5












